Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study

INTRODUCTION: Hyperexcitability and epileptiform activity are commonplace in Alzheimer's disease (AD) patients and associated with impaired cognitive function. The anti‐seizure drug levetiracetam (LEV) is currently being evaluated in clinical trials for ability to reduce epileptiform activity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Onos, Kristen D., Quinney, Sara K., Jones, David R., Masters, Andrea R., Pandey, Ravi, Keezer, Kelly J., Biesdorf, Carla, Metzger, Ingrid F., Meyers, Jill A., Peters, Johnathon, Persohn, Scott C., McCarthy, Brian P., Bedwell, Amanda A., Figueiredo, Lucas L., Cope, Zackary A., Sasner, Michael, Howell, Gareth R., Williams, Harriet M., Oblak, Adrian L., Lamb, Bruce T., Carter, Gregory W., Rizzo, Stacey J. Sukoff, Territo, Paul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398229/
https://www.ncbi.nlm.nih.gov/pubmed/36016830
http://dx.doi.org/10.1002/trc2.12329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398229/
https://www.ncbi.nlm.nih.gov/pubmed/36016830
http://dx.doi.org/10.1002/trc2.12329

Ejemplares similares